Area of research
Genetics · Pathology and Forensic Medicine
Research interest
Research interests include Chronic Lymphocytic Leukemia Research, Lymphoma Diagnosis and Treatment, Epigenetics and DNA Methylation, and Immunodeficiency and Autoimmune Disorders.
NOTCH1 signaling is dysregulated by loss of the deubiquitinase USP28 with del(11q), uncovering USP28 inhibition as novel therapeutic target in CLL
A noncoding mutation in the <i>NOTCH1</i> gene initiates oncogenic NOTCH signaling via wild-type NICD stabilization in CLL
NOTCH1 signaling is dysregulated by loss of the deubiquitinase USP28 with del(11q), uncovering USP28 inhibition as novel therapeutic target in CLL.
A noncoding mutation in the NOTCH1 gene initiates oncogenic NOTCH signaling via wild-type NICD stabilization in CLL.
The NOTCH1 and miR-34a signaling network is affected by <i>TP53</i> alterations in CLL
Acquired <i>BTK</i> mutations associated with resistance to noncovalent BTK inhibitors
Acquired BTK mutations associated with resistance to noncovalent BTK inhibitors.
Nucleosome repositioning in chronic lymphocytic leukemia
Predictive value of DNA methylation patterns in AML patients treated with an azacytidine containing induction regimen
Evaluation of vecabrutinib as a model for noncovalent BTK/ITK inhibition for treatment of chronic lymphocytic leukemia.
Hydroxylation of the NOTCH1 intracellular domain regulates Notch signaling dynamics
Modeling the B‐cell receptor signaling on single cell level reveals a stable network circuit topology between nonmalignant B cells and chronic lymphocytic leukemia cells and between untreated cells and cells treated with kinase inhibitors
Genetic Markers and Front Line FCR/BR Vs. Rve, Gve and Give Treatment - Outcome Results from the CLL13/GAIA Trial
Modeling the B-cell receptor signaling on single cell level reveals a stable network circuit topology between nonmalignant B cells and chronic lymphocytic leukemia cells and between untreated cells and cells treated with kinase inhibitors.
Nucleosome repositioning in chronic lymphocytic leukaemia
NOTCH1 Signaling Is Dysregulated in CLL By the Deubiquitinase USP28 That Is Recurrently Affected By Del(11q) and Can be Therapeutically Targeted
To β or Not to β: How Important Is β-Catenin Dependent and Independent WNT Signaling in CLL?
To β or Not to β: How Important Is β-Catenin Dependent and Independent WNT Signaling in CLL?
Discovery of Candidate DNA Methylation Cancer Driver Genes
Evaluation of vecabrutinib as a model for noncovalent BTK/ITK inhibition for treatment of chronic lymphocytic leukemia
Multi-platform profiling characterizes molecular subgroups and resistance networks in chronic lymphocytic leukemia
Clonal evolution in chronic lymphocytic leukemia is scant in relapsed but accelerated in refractory cases after chemo(immune) therapy
Integrative prognostic models predict long-term survival after immunochemotherapy in chronic lymphocytic leukemia patients
Triggering T-cell activity in CLL.
Prognostic and predictive impact of genetic markers in patients with CLL treated with obinutuzumab and venetoclax
Prognostic and predictive impact of genetic markers in patients with CLL treated with obinutuzumab and venetoclax.
HDAC3 functions as a positive regulator in Notch signal transduction
HDAC3 functions as a positive regulator in Notch signal transduction.
Genomic alterations in high-risk chronic lymphocytic leukemia frequently affect cell cycle key regulators and NOTCH1-regulated transcription.
Oxidative stress as candidate therapeutic target to overcome microenvironmental protection of CLL.